WuXi Biologics Revolutionizes Biologics Development at Basel 2026 Event
WuXi Biologics emphasizes that the key to advancing biologics development processes lies in making early-stage processes faster and more predictable. Their WuXia™ TrueSite Targeted Integration platform, which has been utilized in over 70 projects, achieves average clone titers of 8 g/L and nearly 100% clone stability. Such advancements significantly mitigate downstream development risks while expediting the journey towards IND submission.
Having introduced the clone-derived six-month DNA-to-IND solution six years ago, WuXi Biologics has effectively reduced development timelines while using clones that avoid comparability risks associated with pooled materials. Since its implementation, this platform has successfully supported 66 accelerated programs, propelling six assets into late-stage and commercial manufacturing.
As the variety of biologics expands, selecting the appropriate production pathway and manufacturing platform is becoming increasingly critical. Rather than applying a one-size-fits-all development model, companies now require tailored platforms that can effectively meet specific challenges related to biological properties and production scalability.
As part of this evolution, WuXi Biologics is broadening its developmental capabilities beyond traditional mammalian expression systems. Their strategy now incorporates microbial and HEK293 platforms, accommodating a range of biologics including enzymes, cytokines, antibody fragments, nanobodies, and recombinant proteins. For instance, the microbial platform is gaining traction, playing an essential role as microbial-derived biologics become more prevalent within the industry. WuXi Biologics has accumulated substantial experience from over 3,000 fermentation runs across more than 140 molecules, achieving commercial-scale success at 15,000 liters. This knowledge-driven approach has yielded significant benefits:
These advancements not only enhance predictability but also fortify the economic viability of biologics development, with several programs reporting total cost reductions of 40-50% due to manufacturing innovations and optimization strategies.
In today’s fast-evolving healthcare environment, the design and delivery methods of biologics are pivotal in securing a competitive edge. High-concentration formulations, effectively delivered through subcutaneous methods, have surged in importance as healthcare systems pursue enhanced patient experiences. WuXi Biologics has spearheaded numerous formulation and drug product processes in response to these challenges. To date, they have supported over:
The company’s WuXiHigh™ 2.0 platform further boosts formulation screening from 8 to 24 variations simultaneously, achieving viscosity reductions of up to 90%. This innovation allows for the realization of concentration levels that were previously deemed impractical. Current innovations are extending into ultra-high concentrations with protein levels up to 500 mg/mL, paving the way for next-generation administration methods.
At the heart of WuXi Biologics' mission is the goal to transform scientific innovation into reliable commercial supply. With a global biomanufacturing capacity exceeding 600,000 liters, strategically distributed across locations in Ireland, Germany, Singapore, the U.S., and China, WuXi Biologics is set to meet regional demand and adapt to future market needs.
The company’s reputation for excellence is evidenced by a 100% success rate in PPQ campaigns, delivering more than 2,600 drug substance batches with a commendable 98.7% success rate and achieving a 99.6% success rate across 2,670 drug product batches. As companies approach commercialization, the effective transfer of technology plays a crucial role in bridging the gap between development speed and readiness for manufacturing. With over 220 transfer-in projects successfully completed, WuXi Biologics continues to define the path toward agile and resilient supply chains.
WuXi Biologics emphasizes the value of adopting a holistic, integrated CRDMO model, which combines discovery, CMC, manufacturing, and commercial supply collaboration under a unified approach. As biologics increasingly become more sophisticated, the need for streamlined decision-making and reduced handoffs within the product lifecycle is paramount.
The future of innovation in biologics is not merely about creating more advanced therapeutic options but ensuring they reach patients swiftly and reliably. WuXi Biologics stands ready to be a partner for organizations navigating the complexities of biologics, facilitating smoother transitions from scientific breakthroughs to market realities.
WuXi Biologics (2269.HK) is a prominent global Contract Research, Development and Manufacturing Organization (CRDMO), dedicated to offering comprehensive solutions that empower partners in the discovery, development, and manufacture of biologics. With a team of over 14,000 employees across multiple regions, WuXi Biologics continues to drive efficiency and scalability in biologics solutions, supporting a vast array of client projects effectively. Their commitment to sustainability and excellence in Environmental, Social, and Governance (ESG) practices ensures that they not only meet current market demands but also establish a framework for long-term growth.
Having introduced the clone-derived six-month DNA-to-IND solution six years ago, WuXi Biologics has effectively reduced development timelines while using clones that avoid comparability risks associated with pooled materials. Since its implementation, this platform has successfully supported 66 accelerated programs, propelling six assets into late-stage and commercial manufacturing.
The Right Pathway for the Right Molecule
As the variety of biologics expands, selecting the appropriate production pathway and manufacturing platform is becoming increasingly critical. Rather than applying a one-size-fits-all development model, companies now require tailored platforms that can effectively meet specific challenges related to biological properties and production scalability.
As part of this evolution, WuXi Biologics is broadening its developmental capabilities beyond traditional mammalian expression systems. Their strategy now incorporates microbial and HEK293 platforms, accommodating a range of biologics including enzymes, cytokines, antibody fragments, nanobodies, and recombinant proteins. For instance, the microbial platform is gaining traction, playing an essential role as microbial-derived biologics become more prevalent within the industry. WuXi Biologics has accumulated substantial experience from over 3,000 fermentation runs across more than 140 molecules, achieving commercial-scale success at 15,000 liters. This knowledge-driven approach has yielded significant benefits:
- - Development timelines accelerated by 30-50%.
- - More than 95% first-time scale-up success rates.
- - Streamlined drug substance release timelines reduced to approximately 9.5 months.
- - Technology transfers for BLA timelines shrunk from about 30 months to as little as 18 months.
These advancements not only enhance predictability but also fortify the economic viability of biologics development, with several programs reporting total cost reductions of 40-50% due to manufacturing innovations and optimization strategies.
Greater Patient Convenience
In today’s fast-evolving healthcare environment, the design and delivery methods of biologics are pivotal in securing a competitive edge. High-concentration formulations, effectively delivered through subcutaneous methods, have surged in importance as healthcare systems pursue enhanced patient experiences. WuXi Biologics has spearheaded numerous formulation and drug product processes in response to these challenges. To date, they have supported over:
- - 500 formulation processes.
- - 180 high-concentration biologics programs.
- - 130 projects targeting concentrations up to 240 mg/mL.
- - 30 syringe and combination-device programs.
The company’s WuXiHigh™ 2.0 platform further boosts formulation screening from 8 to 24 variations simultaneously, achieving viscosity reductions of up to 90%. This innovation allows for the realization of concentration levels that were previously deemed impractical. Current innovations are extending into ultra-high concentrations with protein levels up to 500 mg/mL, paving the way for next-generation administration methods.
Ensuring Consistent Commercial Supply
At the heart of WuXi Biologics' mission is the goal to transform scientific innovation into reliable commercial supply. With a global biomanufacturing capacity exceeding 600,000 liters, strategically distributed across locations in Ireland, Germany, Singapore, the U.S., and China, WuXi Biologics is set to meet regional demand and adapt to future market needs.
The company’s reputation for excellence is evidenced by a 100% success rate in PPQ campaigns, delivering more than 2,600 drug substance batches with a commendable 98.7% success rate and achieving a 99.6% success rate across 2,670 drug product batches. As companies approach commercialization, the effective transfer of technology plays a crucial role in bridging the gap between development speed and readiness for manufacturing. With over 220 transfer-in projects successfully completed, WuXi Biologics continues to define the path toward agile and resilient supply chains.
The Future of Biologics Development
WuXi Biologics emphasizes the value of adopting a holistic, integrated CRDMO model, which combines discovery, CMC, manufacturing, and commercial supply collaboration under a unified approach. As biologics increasingly become more sophisticated, the need for streamlined decision-making and reduced handoffs within the product lifecycle is paramount.
The future of innovation in biologics is not merely about creating more advanced therapeutic options but ensuring they reach patients swiftly and reliably. WuXi Biologics stands ready to be a partner for organizations navigating the complexities of biologics, facilitating smoother transitions from scientific breakthroughs to market realities.
About WuXi Biologics
WuXi Biologics (2269.HK) is a prominent global Contract Research, Development and Manufacturing Organization (CRDMO), dedicated to offering comprehensive solutions that empower partners in the discovery, development, and manufacture of biologics. With a team of over 14,000 employees across multiple regions, WuXi Biologics continues to drive efficiency and scalability in biologics solutions, supporting a vast array of client projects effectively. Their commitment to sustainability and excellence in Environmental, Social, and Governance (ESG) practices ensures that they not only meet current market demands but also establish a framework for long-term growth.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.